Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bristol-Myers Squibb Co Receives U.S. FDA therapy designation for all-oral daclatasvir dual investigational regimen for Chronic Hepatitis C


Tuesday, 25 Feb 2014 05:59am EST 

Bristol-Myers Squibb Co:U.S. Food and Drug Administration (FDA) has granted its investigational DCV Dual Regimen (daclatasvir and asunaprevir) Breakthrough Therapy Designation for use as combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).Saus designation is based on data from the company's ongoing Phase III clinical trial program evaluating the all-oral combination regimen of DCV, an investigational NS5A replication complex inhibitor, and ASV, an investigational NS3 protease inhibitor, without ribavirin. 

Company Quote

980.15
 --
15 Dec 2014